EpiVax Therapeutics

EpiVax Therapeutics, Inc. uses immunoinformatics to develop novel vaccines and improve the immunogenicity profiles of biotherapeutics. The company is well-known for its independent thinking and interdisciplinary team of scientists. Out-of-the-box thinking at EpiVax often leads to paradigm-shifting discoveries. EpiVax counts six of the top eight global biotechnology companies among its clients. Founded in 1998 with support from Slater Biotechnology Fund, EpiVax was invited by the FDA in 2002 to participate in the first-ever conference on "Immunogenicity." By 2006, EpiVax had established itself as a "thought leader" in the field of therapeutic proteins and immunogenicity screening, providing fee-for-service solutions to top-tier pharmaceutical companies, small-to-midsize biotech firms, and academia. The company has an impressive track record of publications in academic journals (>170 publications compared to <20 for competitors). EpiVax’s 28 employees form "an incredibly creative team."